VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 335 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2017. The put-call ratio across all filers is 1.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $4,531,000 | +519.8% | 194,800 | +324.4% | 0.02% | +566.7% |
Q1 2018 | $731,000 | -90.5% | 45,900 | -87.5% | 0.00% | -90.9% |
Q4 2017 | $7,708,000 | +125.1% | 368,617 | +53.9% | 0.03% | +120.0% |
Q3 2017 | $3,425,000 | -74.3% | 239,525 | -68.8% | 0.02% | -75.0% |
Q2 2017 | $13,346,000 | +23314.0% | 768,929 | +14977.0% | 0.06% | – |
Q1 2017 | $57,000 | -94.4% | 5,100 | -92.7% | 0.00% | -100.0% |
Q4 2016 | $1,009,000 | -90.3% | 69,500 | -83.7% | 0.01% | -90.4% |
Q3 2016 | $10,411,000 | +177.8% | 425,100 | +127.5% | 0.05% | +173.7% |
Q2 2016 | $3,748,000 | +4527.2% | 186,884 | +5928.5% | 0.02% | – |
Q1 2016 | $81,000 | -72.4% | 3,100 | +6.9% | 0.00% | -100.0% |
Q4 2015 | $293,000 | -25.1% | 2,900 | +31.8% | 0.00% | 0.0% |
Q3 2015 | $391,000 | -34.7% | 2,200 | -18.5% | 0.00% | -33.3% |
Q2 2015 | $599,000 | – | 2,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |